## STANDARD COMMERCIAL DRUG FORMULARY PRIOR AUTHORIZATION GUIDELINES

GANAXOLONE

| Generic | Brand | HICL | GCN | Medi-Span | Exception/Other |
| :--- | :--- | :--- | :--- | :--- | :--- |
| GANAXOLONE | ZTALMY | 47912 |  | GPI-10 <br> $(7260003300)$ |  |

## GUIDELINES FOR USE

1. Does the patient have a diagnosis of seizures and meet ALL of the following criteria?

- The patient is 2 years of age or older
- The patient's seizures are associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD)

If yes, approve for 12 months by HICL or GPI-10 with a quantity limit of \#36 mL per day. If no, do not approve.
DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named GANAXOLONE (Ztalmy) requires the following rule(s) be met for approval:
A. You have seizures
B. You are 2 years of age or older
C. Your seizures are associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD: a type of genetic disorder)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

## RATIONALE

For further information, please refer to the Prescribing Information and/or Drug Monograph for Ztalmy.

## REFERENCES

- Ztalmy [Prescribing Information]. Radnor, PA: Marinus Pharmaceuticals, Inc.; June 2022.

| Library | Commercial | NSA |
| :--- | :--- | :--- |
| Yes | Yes | No |

Part D Effective: N/A
Commercial Effective: 10/01/22

Created: 08/22
Client Approval: 09/22

P\&T Approval: 07/22

[^0]
[^0]:    Copyright © 2022 Medlmpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to Medlmpact. Medlmpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.

